Vis Medicatrix Naturae

Donald Brown, ND

Over the past several years, there have been large projects collecting data to examine the role that the human microbiota plays in health and disease.^{1, 2} One of the primary areas of focus has been the role that microbial communities play in the health of the female genitourinary tract. The Vaginal Microbiome Consortium at Virginia Commonwealth University is a 2-stage project funded by the National Institutes of Health; it involves collecting vaginal samples from over 6000 women 18 years and older in the first stage, and samples from 2000 pregnant women in the second stage.³ The objective of the latter study is to elucidate the role(s) that the vaginal microbiota plays in the etiology of adverse outcomes of pregnancy and, more specifically, preterm birth.

Normal Vaginal Microbiota & Function

While the gastrointestinal (GI) tract harbors an estimated 500 different microbial species, the number of species inhabiting the vagina is thought to be approximately 50.⁴ Vaginal eubiosis is characterized by the presence of beneficial lactic-acid-producing microbes that are largely dominated by the genus Lactobacillus; these typically make up 90-95% of the total bacterial count in the genitourinary tract.⁵ The vaginal microbiota during eubiosis in reproductive-age women is typically dominated by Lactobacillus crispatus, L gasseri, L iners, and L jensenii, most of which produce large amounts of lactic acid.⁶ Other species identified have included L acidophilus, L rhamnosus, L plantarum, L fermentum, L brevis, L casei, L vaginalis, L delbruekii, L salivarius, and L reuteri.⁷ In contrast, vaginal dysbiosis is characterized by the presence of polymicrobial populations with either a modest lactobacilli load (intermediate microbiota) or no lactobacilli (bacterial vaginosis [BV]).⁸ In short, as opposed to the GI tract, healthy vaginal flora is less diverse.

Lactobacillus species in the vagina contribute a number of health promoting and protective factors in women. These include:

• Production of lactic acid, which is primarily responsible for acidification, thus serving as a antimicrobial factor.⁹ L crispatus, on average, produces the highest amount of lactic acid.⁶
• Competitive inhibition of binding of pathogenic bacteria, including those responsible for yeast vaginitis, bacterial vaginosis, urinary tract infections, and sexually transmitted infections^10-14
• Disruption of the formation of uropathogen-related biofilms, 15 of which protect pathogens and enable colonization of normal flora such as Candida spp¹⁶
• Regulation of vaginal epithelial cell innate immunity¹⁷

A strain of L acidophilus has also been found to reduce fecal beta-glucuronidase levels and activity and support healthy estrogen metabolism.¹⁸ While many Lactobacillus probiotics for women’s health have been chosen based on production of hydrogen peroxide (H₂O₂), recent studies suggest that in the hypoxic conditions of the vagina, concentrations of H₂O₂ do not achieve levels that would be antimicrobial.¹⁹

Many factors influence the stability and population of the vaginal microbiota. The composition of vaginal communities fluctuates as a function of age, menarche, menses, pregnancy, infections, birth control, and sexual behaviors.²⁰ Exposure to spermicides or b-lactam or other antimicrobials can decrease the prevalence of lactobacilli and consequently increase susceptibility to genitourinary tract infections.²¹

Probiotics & Genitourinary Tract Health

Probiotics are defined as living organisms administered to promote the health of the host. Specifically, a recent revision to the original FAO/WHO workshop defined probiotics as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.”²² Most of the scientific and clinical research with probiotics has focused on oral use of probiotics for gastrointestinal and immune health. The primary genera that have been studied are Lactobacillus and Bifidobacteria species.

Many of the initial studies looking at the potential benefits of probiotics for female genitourinary tract health focused on the intravaginal application of lactobacilli strains. There has been an emerging trend, however, of using oral probiotics to colonize the vagina, backed by a substantial amount of clinical research. Numerous trials have demonstrated that oral administration of specific strains of lactobacilli – in particular, L crispatus, L rhamnosus, L gasseri, and L reuteri – can both maintain and restore healthy genitourinary microbiota in females.^23-25 A recent study found that oral supplementation with L acidophilus and L rhamnosus in women with intermediate vaginal microbiota (having only modest levels of Lactobacillus spp) led to significant vaginal colonization of both strains and a restoration of normal Nugent scores.²⁶

Vaginal & Urinary Tract Infections

Bacterial Vaginosis

Bacterial vaginosis (BV) is a common vaginal infection causing significant gynecological and obstetric morbidity. Though no single pathogen has been identified as the causative agent of BV, Gardnerella vaginalis and Atopobium vaginae are commonly associated with the condition.²⁷ Typical symptoms may include vaginal malodor, itching, dysuria, and a thin discharge, but a substantial number of women with BV are also asymptomatic.²⁸ BV has been associated with pelvic inflammatory disease, infections following gynecological surgery, and preterm birth.²⁹ Estimates suggest that 40% of cases of spontaneous preterm labor and preterm birth maybe associated with BV.³⁰

Two randomized, double-blind, placebo-controlled trials (RDBPCT) have shown that the addition of probiotics to standard treatment of BV (metronidazole and tinidazole) improve the eradication of BV symptoms.^31,32 Both trials used a combination of L rhamnosus and L reuteri (1 billion colony-forming units [CFU]/day of each strain) both during and after standard treatment for BV, collectively resulting in the use of probiotics for 28 days in the first trial and 30 days in the second. In both studies, there was a significantly higher “cure” rate in women taking the oral probiotic combination compared to the placebo group. In the first trial, high counts of Lactobacillus species were also recovered from the vagina of women treated with the oral probiotic combination.³¹

Vulvovaginal Candidiasis

Vulvovaginal candidiasis (VVC) is most commonly associated with Candida albicans and C glabrata.³³ While the clinical data on the use of probiotics is not as robust as that for BV, there are a couple of interesting studies.

In one RDBPCT, researchers explored whether probiotics could reduce the risk of recurrence of VVC after a standard course of treatment with fluconazole.³⁴ After initial treatment with a single dose of oral fluconazole, 59 VVC patients took either an oral probiotic supplement (containing a combination of 7.5 billion CFU of L acidophilus, 6 billion CFU of Bifidobacterium bifidum, and 1.5 billion CFU of B longum) or placebo capsules daily for 6 months. Of the women taking placebo capsules, 35.5% experienced recurrence of VVC; of the women taking probiotics, only 7.2% experienced recurrence. Another RDBPCT found that oral use of L rhamnosus and L reuteri (1 billion CFU/day of each strain) led to better outcomes in women taking fluconazole for VVC.³⁵

Urinary Tract Infections

Approximately 50% of all women will also be plagued by urinary tract infections (UTIs) during their lifetime, with nearly 1 in 3 women having a UTI by the age of 24.³⁶ Growing concerns about antibiotic resistance have led to increased interest in non-antibiotic therapies for recurrent UTIs.

A 12-month clinical trial with 252 postmenopausal women having recurrent UTIs compared a probiotic combination to trimethoprim-sulfamethoxazole (TMP-SMX) for the reduction of UTI recurrence.³⁷ Women were randomized to (1) TMP-SMX, 480 mg (1 tablet at night) and 1 placebo capsule twice daily; or (2) 1 capsule containing L rhamnosus and L reuteri  (1 billion CFU/day of each strain) twice daily and 1 placebo tablet at night. After 12 months, the mean number of symptomatic UTIs (clinical recurrences) was 2.9 in the antibiotic group and 3.3 in the probiotic group, compared to a mean number of symptomatic UTIs of 7.0 and 6.8 in the year prior for these groups, respectively. The between-group difference in clinical recurrences after the 12-month intervention was not found to be significant. The median time to a recurrence was 3 months in the probiotic group and 6 months in the antibiotic group. However, the antibiotic group was found to have a more than 2-fold increase in resistance to both TMP-SMX and amoxicillin, while the probiotic group showed no increase in antibiotic resistance. The study investigators conclude “lactobacilli may be an acceptable alternative for prevention of UTIs, especially in women who dislike taking antibiotics.”³⁷

Pregnancy

Preterm birth can be defined as delivery before 37 completed weeks of gestational age.³⁸ Preterm birth comprises 11% of all live births worldwide, and its complications are estimated to cause 35% of the world’s neonatal deaths, or about 11 million deaths annually.³⁹

As noted in the BV section above, BV is one of the most common risk factors for preterm birth. A recent Canadian study compared the vaginal microbiome of pregnant women who had spontaneous preterm births with pregnant women who delivered at term.⁴⁰ The findings suggested that women who experienced preterm birth were more likely to show more diverse vaginal bacteria (primarily those associated with dysbiosis) and less lactobacilli compared to those who delivered at term. While a causal relationship still needs to be studied further, women who delivered at term were more likely to cluster to groups with vaginal microbiota dominated by L crispatus and L gasseri.

In addition to pregnancy outcomes, the use of probiotics preterm has been associated with a decreased risk of postpartum depression and anxiety,⁴¹ gestational diabetes mellitus,⁴² and infant atopic dermatitis (taken preterm and post-term).⁴³

Conclusion

Female urogenital infections (such as BV, VVC, and UTIs) and preterm birth affect billions of women each year, resulting in considerable morbidity and healthcare costs. Options for the prevention and treatment of these common conditions are limited, particularly for women with recurrent infections. Clinical data point to the importance of a healthy vaginal microbiome as an approach to potentially reducing the incidence of these infections as well as improving pregnancy outcomes. Oral probiotic products containing combinations of Lactobacillus strains have emerged as a safe and effective way for women of all ages to re-establish and maintain healthy vaginal microbiota.

References:

1. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. 2007;449(7164):804-810.
2. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
3. Huang B, Fettweiss JM, Brooks JP, et al. The changing landscape of the vaginal microbiome. Clin Lab Med. 2014;34(4):747-761.
4. Waigankar SS, Patel V. Role of probiotics in urogenital healthcare. J Midlife Health. 2011;2(1):5-10.
5. Sirota I, Zarek SM, Segars JH. Potential influence of the microbiome on infertility and assisted reproductive technology. Semin Reprod Med. 2014;32(1):35-42.
6. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4680-4687.
7. Vásquez A, Jakeobsson T, Ahrmé S, et al. Vaginal lactobacillus flora of healthy Swedish women. J Clin Microbiol. 2002;40(8):2746-2749.
8. Borges S, Silva J, Teixiera P. The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet. 2014;289(3):479-489.
9. Techedjan G, Aldunate M, Bradshaw CS, Cone RA. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol. 2017;168(9-10):782-792.
10. Gupta K, Stapleton AE, Hooten TM, et al. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis. 1998;178(2):446-450.
11. Hillier SL, Krohn MA, Klebanoff SJ, Eshenbach DA. The relationship of hydrogen peroxide- producing lactobacilli to bacterial vaginosis and genital microflora in pregnant women. Obstet Gynecol. 1992;79(3):369-373.
12. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet. 1997;350(9077):546-550.
13. Sobel JD. Is There a Protective Role for Vaginal Flora? Curr Infect Dis Rep. 1999;1(4):379-383.
14. van De Wijgert JH, Mason PR, Gwanzura L, et al. Intravaginal practices, vaginal flora disturbances, and acquisition of sexually transmitted diseases in Zimbabwean women. J Infect Dis. 2000;181(2):587-594.
15. McMillan A, Dell A, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86(1):58-64.
16. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003;11(1):30-36.
17. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. J Infect Dis. 2014;209(12):1989-1999.
18. Ayebo AD, Angelp IA, Shahani KM. Effect of ingesting Lactoacidophilus acidophilus milk upon fecal flora and enzyme activity in humans. Milchwissenschaft. 1980;35(12):730-735.
19. O’Hanlon DE, Moench TR, Cone RA. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One. 2013;8(11):e80074.
20. Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012;4(132):132ra52.
21. Hooton TM, Fennell CL, Clark AM, Stamm WE. Nonoxynol-9 differential antibacterial activity and enhancement of bacterial adherence to vaginal epithelial cells. J Infect Dis. 1991;164(6):1216-1219.
22. Hill C, Guarmer F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014:11(8):506-514.
23. Strus M, Chimielarczyk A, Kochan P, et al. Studies on the effects of probiotic Lactobacillus mixture given orally on vaginal and rectal colonization and on parameters of vaginal health in women with intermediate vaginal flora. Eur J Obstet Gynecol Reprod Biol. 2012;163(2):210-215.
24. Reid G, Bruce AW, Fraser N, et al. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol. 2001;30(1):49-52.
25. Petricevic L, Unger FM, Viernstein H, Kiss H. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):54-57.
26. De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta(Ò) complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861-867.
27. Bradshaw CS, Tabrizi SN, Fairley CK, et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis. 2006;194(6):828-836.
28. Klebanoff MA, Schwebke JR, Zhang J, et al. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol. 2004;104(2):267-722.
29. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007;13(7):657-664.
30. Pretorius C, Jagatt A, Lamont RF. The relationship between periodontal disease, bacterial vaginosis, and preterm birth. J Perinat Med. 2007;35(2):93-99.
31. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8(6):1450-1454.
32. Martinez RC, Franceschini SA, Patta MC, et al. Improved cure of bacterial vaginosis with single dose tinidazole (2 g), Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo controlled trial. Can J Microbiol. 2009;55(2):133-138.
33. Vermitsky JP, Self MJ, Chadwick SG, et al. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol. 2008;46(4):1501-1503.
34. Davar R, Nokhostin F, Eftekhar M, et al. Comparing the recurrence of vulvovaginal candidiasis in patients undergoing prophylactic treatment with probiotic and placebo during the 6 months. Probiotics Antimicrob Proteins. 2016;8(3):130-313.
35. Martinez RC, Franceschini SA, Patta MC, et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol. 2009;48(3):269-274.
36. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49:53-70.
37. Beereport MA, ter Riet G, Nys S, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704-712.
38. Quinn JA, Munoz FM, Gonik B, et al. Preterm birth: case definition and guideines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34(49):6047-6056.
39. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162-2172.
40. Freitas AC, Bocking A, Hill JE, et al. Increased richness and diversity of the vaginal microbiota and spontaneous preterm birth. 2018;6(1):117.
41. Slykerman RF, Hood F, Wickens K, et al. Effect of Lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: A randomized double-blind placebo-controlled trial. EBioMedicine. 2017;24:159-165.
42. Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomized controlled trial. Br J Nutr. 2017;117(6):804-813.
43. Zuccotti G, Meneghin F, Aceti A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy. 2015;70(11):1356-1371.

Donald Brown, ND, is one of the leading authorities in the United States on the safety and efficacy of dietary supplements, evidence-based herbal medicine, and probiotics. Dr Brown currently serves as the director of Natural Product Research Consultants (NPRC) in Seattle, WA. He is a member of the Advisory Board of the American Botanical Council (ABC) and the Editorial Board of The Integrative Medicine Alert. Dr Brown is the author of Herbal Prescriptions for Health and Healing and was also a contributor to The Natural Pharmacy, the A-Z Guide to Drug-Herb-Vitamin Interactions, and The Textbook of Natural Medicine.